Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Albumin-Bound Paclitaxel in Breast Cancer
NCT06765590Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of Paclitaxel Micelles for Injection in breast cancer (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum observed concentration of paclitaxel, Area under the concentration-time curve from time zero to infinite time and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06765590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765590.